Literature DB >> 19114873

Updates on cytochrome P450-mediated cardiovascular drug interactions.

Judy W M Cheng1, William H Frishman, Wilbert S Aronow.   

Abstract

Cytochrome P (CYP) 450 is a superfamily of hemoproteins that play an important role in the metabolism of steroid hormones, fatty acids, and many medications. Many agents used for management of cardiovascular diseases are substrates, inhibitors, or inducers of CYP450 enzymes.When two agents that are substrates, inhibitors, or inducers of CYP450 are administered together, drug interactions with significant clinical consequences may occur. This review discusses CYP450-mediated cardiovascular drug interactions as well as noncardiovascular drug interactions that produced significant cardiovascular side effects. The principles in predicting drug interactions are also discussed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19114873     DOI： 10.1097/MJT.0b013e31813e63be

Source DB:  PubMed          Journal:  Am J Ther        ISSN： 1075-2765            Impact factor:   2.688


  5 in total

Review 1.  [Clinically relevant pharmacokinetic drug interactions in the intensive care unit: an overview].

Authors:  W Kämmerer
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-03-23       Impact factor: 0.840

Review 2.  Cardiovascular drug therapy in the elderly: benefits and challenges.

Authors:  Jerome L Fleg; Wilbert S Aronow; William H Frishman
Journal:  Nat Rev Cardiol       Date:  2010-10-26       Impact factor: 32.419

3.  HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis.

Authors:  Joel D Mermis; Steven Q Simpson
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 4.  Lipid-lowering Therapies in Myositis.

Authors:  Marisa C Mizus; Eleni Tiniakou
Journal:  Curr Rheumatol Rep       Date:  2020-08-26       Impact factor: 4.592

5.  Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.

Authors:  Maciej Banach; Manfredi Rizzo; Peter P Toth; Michel Farnier; Michael H Davidson; Khalid Al-Rasadi; Wilbert S Aronow; Vasilis Athyros; Dragan M Djuric; Marat V Ezhov; Robert S Greenfield; G Kees Hovingh; Karam Kostner; Corina Serban; Daniel Lighezan; Zlatko Fras; Patrick M Moriarty; Paul Muntner; Assen Goudev; Richard Ceska; Stephen J Nicholls; Marlena Broncel; Dragana Nikolic; Daniel Pella; Raman Puri; Jacek Rysz; Nathan D Wong; Laszlo Bajnok; Steven R Jones; Kausik K Ray; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2015-03-14       Impact factor: 3.318
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.